RESUMEN
Hepatocellular carcinoma [HCC] represents a major health problem world wide. It accounts for 90% of all primary liver cancers and is the fifth most common malignancy [1]. Evaluation of radiofrequency thermal ablation versus transarterial hepatic chemoembolization with the effect of Viscum [Fraxini 2] on tumour recurrence. 60 patients with HCC were enrolled in the study. Group 1 include 30 patients and were treated with radiofrequency thermal ablation [15 patients of them received viscum 2 by subcutaneous route for 2 years]. Group 11 included 30 patients with HCC and were treated by TACE [15 patients of them received viscum 2 subcutaneously for 2 years]. Group 1 patients showed total ablation in 70% with persistant inactivity during 2 years follow up. Group II did not show significant difference from Group 1 as regards relapse rate nor the performance status. Complications as nausea, vomiting, fever, jaundice, and elevation of transaminases were significantly more encountered with TA CE. Viscum 2 did not significantly arrest tumour recurrence. Non surgical patients with HCC can achieve curative treatment with radiofrequency with minimal side effects. TACE is a palliative treatment option for large HCC